ZURA
NASDAQ · Biotechnology
Zura Bio Ltd
$6.01
+0.34 (+6.00%)
Open$5.72
Previous Close$5.67
Day High$6.11
Day Low$5.59
52W High$27.20
52W Low$16.72
Volume—
Avg Volume771.3K
Market Cap316.66M
P/E Ratio53.74
EPS$0.34
SectorBiotechnology
Analyst Ratings
Strong Buy
13 analysts
Price Target
+284.7% upside
Current
$6.01
$6.01
Target
$23.12
$23.12
$15.51
$23.12 avg
$31.84
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 178.15M | 170.40M | 174.38M |
| Net Income | 4.79M | 4.86M | 5.73M |
| Profit Margin | 2.7% | 2.9% | 3.3% |
| EBITDA | 8.96M | 8.92M | 9.38M |
| Free Cash Flow | 5.34M | 5.40M | 5.82M |
| Rev Growth | +24.5% | +6.4% | +20.2% |
| Debt/Equity | 0.26 | 0.34 | 0.36 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |